Wednesday, October 14, 2026
ExploreSearch
Finance Via News
Via News Knowledge File

Broadcom Inc.

organization80% conf.·synced Oct 14, 2026

Semiconductor and infrastructure software company specializing in AI accelerators, networking, and enterprise software

60
sourced metrics
908
relationships
20
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Stock Price
357.31USD
Oct 13, 2026reference only
Price 52 Week High
481.57USD
Oct 13, 2026reference only
Price 52 Week Low
293.41USD
Oct 13, 2026reference only
Stock Return Ytd
2.8%
Oct 13, 2026reference only
Market Cap
1699930980547USD
Oct 13, 2026reference only
Shares Outstanding
4757580198.0shares
May 29, 2026reference only
Rd Expense
2995000000.0USD
May 3, 2026reference only
Revenue
22187000000.0USD
May 3, 2026reference only
Operating Income
10788000000.0USD
May 3, 2026reference only
Eps
1.91USD_per_share
May 3, 2026reference only
Total Assets
179158000000.0USD
May 3, 2026reference only
Cash
19628000000.0USD
May 3, 2026reference only
Cost Of Revenue
6772000000.0USD
May 3, 2026reference only
Gross Profit
15415000000.0USD
May 3, 2026reference only
Total Liabilities
91467000000.0USD
May 3, 2026reference only
Operating Cash Flow
8260000000.0USD
Feb 1, 2026reference only
Capex
250000000.0USD
Feb 1, 2026reference only

Stated objectives

Q1 FY2026 AI semiconductor revenue target doubling YoY

source
target: 8200000000 USD by 2026-03-31 00:00:00stated

Q1 FY2026 adjusted EBITDA margin target

source
target: 67 percent by 2026-03-31 00:00:00stated

FY2026 infrastructure software low double-digit growth driven by VMware

source
target: Low double-digit percent by 2026-12-31 00:00:00stated

FY2026 annual dividend per share target

source
target: 2.60 USD by 2026-12-31 00:00:00stated

Ship $73B AI backlog over next 18 months

source
target: 73000000000 USD by 2027-06-30 00:00:00stated

Q1 FY2026 revenue target of approximately $19.1B

source
target: 19100 by 2026-02-01 00:00:00stated

Q1 FY2026 adjusted EBITDA target of 67% of revenue

source
target: 67 by 2026-02-01 00:00:00stated

Q1 FY2026 AI semiconductor revenue target of $8.2B, doubling year-over-year

source
target: 8200 by 2026-02-01 00:00:00stated

FY2026 annual dividend target of $2.60 per share

source
target: 2.60 by 2026-11-01 00:00:00stated

Q1 FY2026 total revenue forecast

source
target: 19.1 billion USD stated

Relationship graph · 908 connections

Supplies to
204
Competes with
157
Covered by
137
Developed by
123
Invested in
48
Customer of
47
Employs
38
subsidiary of
22
constituent of
NYSE FANG+ Index

Where sources disagree

We surface conflicts between sources rather than hiding them.

value conflictunresolved

FACT A reports Broadcom's cash as 16.178 billion USD for FY 2025, while FACT B reports 16.18 USD for Q4 2025. These represent the same measurement point in time (end of fiscal year/Q4), not separate periods. The values diverge by approximately 1 billion USD—a factor of 10^9. FACT B's value of $16.18 is also logically implausible for a major semiconductor company. The discrepancy indicates a unit error (FACT B missing 'billion' designation) or data entry error in FACT B.

source B
value conflictunresolved

Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.

source B
value conflictunresolved

Broadcom's operating cash flow is reported as $27.537 billion on 2025-11-02 and $8.26 USD on 2026-02-01. The second value is implausibly low for a major semiconductor company and likely represents corrupted or truncated data (possibly a decimal fragment or percentage misidentified as a full currency value). A realistic operating cash flow cannot collapse from tens of billions to single digits in 3 months.

source B

Via News coverage

Samsung, Nvidia and South Korea Commit Over $1 Trillion to Chip Supply Chains
July 31, 2026
SOXX Up 79% YTD Before 10% Sell-Off as Rising ASIC Costs Lock Out New Entrants
June 11, 2026
Broadcom's 19.5% Post-Guidance Collapse Signals a New Bar for AI Semiconductor Stocks
June 9, 2026
Broadcom Drops 19.5%, NVIDIA Falls 6% as 2-Year Treasury Yield Hits 16-Month High
June 9, 2026
2-Year Treasury Yield Hits 16-Month High, Triggering AI Platform Selloff
June 9, 2026
Broadcom's 19.5% Collapse Exposes Asymmetric Downside Risk in AI Semiconductor Guidance Events
June 9, 2026
Nvidia Acquires Groq as AI Chip Industry Moves to Vertical Integration
May 25, 2026
Meta Moves 7,000 Employees Into AI Divisions, Sets $115B–$135B Capex Target for 2026
May 24, 2026
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com